Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EOS 789

Next Previous
Drug Profile

EOS 789

Alternative Names: AP-306 ; EOS-789

Latest Information Update: 20 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Shanghai Alebund Pharmaceuticals
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action Phosphate transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperphosphataemia

Most Recent Events

  • 13 Dec 2023 Interim efficacy and adverse events data from phase II trial in Hyperphosphataemia released by Alebund Pharmaceuticals
  • 14 Sep 2023 Alebund Pharmaceuticals completes a phase II trial in Hyperphosphataemia in China (PO) (NCT05764590)
  • 27 Feb 2023 EOS 789 is still in phase-I development for Hyperphosphataemia (Combination therapy) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top